Bio-Rad Acquires Scottish Diagnostic Company

By HospiMedica staff writers
Posted on 17 Apr 2002

In a move that expands its line of tests for genetic disorders, Bio-Rad Laboratories, Inc. (Hercules, CA, USA) has acquired Quantase Neonatal Diagnostics, Ltd. (Perth, Scotland). Terms were not disclosed.

Quantase specializes in diagnostic products for newborn screening. The acquisition strengthens Bio-Rad as a supplier of newborn screening tests for phenylketonuria, galactosemia, and glucose-6-phosphate dehydrogenase deficiency. It also enhances the company's position in genetic testing by adding to its portfolio of DNA, immunoassay, and high perfusion liquid chromatography (HPLC) tests for sickle cell anemia, metabolic disorders, and thalassemia.

"This acquisition strengthens our position in serving the genetic screening market and provides a foundation for us to further our innovation in genetic screening products and services,” said David Schwartz, president of Bio-Rad. "Quantase has an excellent reputation for quality products and broad customer acceptance throughout the world.”

Related Links:
Bio-Rad